YU35697A - Substituted 6,6-hetero-bicyclic derivatives - Google Patents

Substituted 6,6-hetero-bicyclic derivatives

Info

Publication number: YU35697A
Authority: YU; Yugoslavia
Prior art keywords: hetero; substituted; bicyclic derivatives; bicyclic; derivatives
Prior art date: 1996-08-27

Application number

YU35697A

Other languages

English (en)

Serbo-Croatian (sh)

Inventor

Liang Chen Yuhpyng

Original Assignee

PFIZER INC.proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware, US,

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1997-08-26

Publication date

1999-11-22

1997-08-26 Application filed by PFIZER INC.proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware, US, filed Critical PFIZER INC.proizvodno i trgovinsko preduzeće organizovano po propisima države Delaware, US,

1999-11-22 Publication of YU35697A publication Critical patent/YU35697A/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)

YU35697A 1996-08-27 1997-08-26 Substituted 6,6-hetero-bicyclic derivatives YU35697A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2465996P	1996-08-27	1996-08-27

Publications (1)

Publication Number	Publication Date
YU35697A true YU35697A (en)	1999-11-22

Family

ID=21821740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
YU35697A YU35697A (en)	1996-08-27	1997-08-26	Substituted 6,6-hetero-bicyclic derivatives

Country Status (40)

Country	Link
EP (1)	EP0925298B1 (sr)
JP (1)	JP2000502722A (sr)
KR (1)	KR100457759B1 (sr)
CN (2)	CN1191236C (sr)
AP (1)	AP1164A (sr)
AR (2)	AR009321A1 (sr)
AT (1)	ATE264327T1 (sr)
AU (1)	AU726771C (sr)
BG (1)	BG64316B1 (sr)
BR (1)	BR9711262A (sr)
CA (1)	CA2263913C (sr)
CO (1)	CO4930259A1 (sr)
CZ (1)	CZ67799A3 (sr)
DE (1)	DE69728676T2 (sr)
DK (1)	DK0925298T3 (sr)
DZ (1)	DZ2299A1 (sr)
EA (1)	EA002607B1 (sr)
ES (1)	ES2216157T3 (sr)
GT (1)	GT199700093A (sr)
HR (1)	HRP970452A2 (sr)
ID (1)	ID18189A (sr)
IL (1)	IL128049A (sr)
IS (1)	IS4970A (sr)
MY (1)	MY132671A (sr)
NO (1)	NO316273B1 (sr)
NZ (1)	NZ333728A (sr)
OA (1)	OA10980A (sr)
PA (1)	PA8435001A1 (sr)
PE (1)	PE108698A1 (sr)
PL (1)	PL331988A1 (sr)
PT (1)	PT925298E (sr)
SI (1)	SI0925298T1 (sr)
SK (1)	SK22599A3 (sr)
TN (1)	TNSN97144A1 (sr)
TR (1)	TR199900408T2 (sr)
TW (1)	TW477787B (sr)
UA (1)	UA66345C2 (sr)
WO (1)	WO1998008846A1 (sr)
YU (1)	YU35697A (sr)
ZA (1)	ZA977652B (sr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
KR20000029843A (ko)	1996-08-06	2000-05-25	디. 제이. 우드;스피겔 알렌 제이	치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체
EP0970082A2 (en) *	1997-02-18	2000-01-12	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
CA2272291C (en) *	1997-04-22	2008-06-17	Janssen Pharmaceutica N.V.	Crf antagonistic quino- and quinazolines
NL1010018C2 (nl) *	1997-09-09	1999-03-10	Duphar Int Res	Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
ATE225349T1 (de)	1998-11-12	2002-10-15	Neurocrine Biosciences Inc	Crf rezeptor-antagonisten und darauf bezogene methoden
PT1129096E (pt)	1998-11-12	2003-09-30	Neurocrine Biosciences Inc	Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
ES2226785T3 (es) *	1999-02-12	2005-04-01	Smithkline Beecham Plc	Derivados de fenilurea como antagonistas de los receptores de orexina.
US6432989B1 (en)	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
AU7738000A (en)	1999-09-30	2001-04-30	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
CN1379678A (zh)	1999-10-01	2002-11-13	强生消费者公司	用个人护理组合物镇静人类的方法
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
US6525067B1 (en) *	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
ATE319103T1 (de)	2000-01-26	2006-03-15	Em Microelectronic Marin Sa	Verfahren zur prüfung einer integrierten schaltung mit vertraulichen software- oder hardware-elementen
AU2001232271A1 (en) *	2000-02-14	2001-08-20	Japan Tobacco Inc.	Preventives/remedies for postoperative stress
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2001087886A1 (en) *	2000-05-18	2001-11-22	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods relating thereto
AU2002246855B2 (en)	2000-10-23	2005-12-22	Smithkline Beecham Corporation	Novel compounds
JP2004528349A (ja)	2001-04-30	2004-09-16	グラクソ　グループ　リミテッド	副腎皮質刺激ホルモン放出因子（ｃｒｆ）のアンタゴニストとしての縮合ピリミジン類
GB0117396D0 (en)	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
GB2384563A (en)	2002-01-29	2003-07-30	Johnson & Johnson Consumer	Method of measuring the stress or relaxation level of a mammal
RU2004133811A (ru)	2002-04-19	2005-04-20	Смитклайн Бичам Корпорейшн (US)	Новые соединения
US7067658B2 (en)	2002-09-30	2006-06-27	Bristol-Myers Squibb Company	Pyridino and pyrimidino pyrazinones
CN102558155A (zh)	2003-01-14	2012-07-11	阿伦纳药品公司	作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) *	2003-07-14	2009-12-03	Arena Pharmaceuticals,Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CN1835753A (zh)	2003-08-12	2006-09-20	弗·哈夫曼-拉罗切有限公司	作为促皮质释放素(cfr)拮抗剂的螺－取代的四氢喹唑啉
EP1656354B1 (en)	2003-08-12	2007-09-26	F.Hoffmann-La Roche Ag	Tetrahydroquinazoline derivatives as cfr antagonists
JP2006232849A (ja) *	2003-08-13	2006-09-07	Japan Tobacco Inc	含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
BRPI0507609A (pt) *	2004-02-13	2007-07-03	Pfizer Prod Inc	combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
DE102004018198A1 (de)	2004-04-15	2005-11-03	Merck Patent Gmbh	Sulfonamide
CA2590294A1 (en)	2004-12-13	2006-06-22	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
PE20100741A1 (es)	2005-03-25	2010-11-25	Glaxo Group Ltd	COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
TWI389690B (zh)	2005-03-25	2013-03-21	Glaxo Group Ltd	新穎化合物（一）
JP2008537937A (ja)	2005-03-25	2008-10-02	グラクソグループリミテッド	ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
WO2006110298A2 (en)	2005-03-25	2006-10-19	Glaxo Group Limited	8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
AU2006228378A1 (en)	2005-03-31	2006-10-05	Pfizer Products Inc.	Cyclopentapyridine and tetrahydroquinoline derivatives
DE602006015861D1 (de)	2005-12-21	2010-09-09	Abbott Lab	Antivirale verbindungen
WO2007081517A2 (en)	2005-12-21	2007-07-19	Abbott Laboratories	Anti-viral compounds
US7910595B2 (en)	2005-12-21	2011-03-22	Abbott Laboratories	Anti-viral compounds
KR101504669B1 (ko) *	2006-10-19	2015-03-20	시그날 파마소티칼 엘엘씨	헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
WO2008133753A2 (en)	2006-12-20	2008-11-06	Abbott Laboratories	Anti-viral compounds
HUE034298T2 (en) *	2007-05-17	2018-02-28	Helperby Therapeutics Ltd	Use of 4- (Pyrrolidin-1-yl) quinoline derivatives to kill clinically latent microorganisms
WO2011156889A1 (en) *	2010-06-14	2011-12-22	Trt Pharma Inc.	Novel modulators of nrf2 and uses thereof
EA201390421A1 (ru)	2010-09-22	2013-09-30	Арена Фармасьютикалз, Инк.	Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
EP2888245B1 (en) *	2012-08-24	2016-09-21	F. Hoffmann-La Roche AG	New bicyclicpyridine derivatives
MX389004B (es)	2014-01-21	2025-03-20	Neurocrine Biosciences Inc	Antagonistas de receptor del factor de liberación de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congénita.
EP4445956A3 (en)	2015-01-06	2024-12-04	Arena Pharmaceuticals, Inc.	Compound for use in treating conditions related to the s1p1 receptor
PE20180395A1 (es)	2015-06-04	2018-02-28	Pfizer	Formas de dosificacion solidas de palbociclib
PL3310760T3 (pl)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
AU2017311645B2 (en)	2016-08-15	2021-05-27	Pfizer Inc.	Pyridopyrimdinone CDK2/4/6 inhibitors
KR102009756B1 (ko)	2017-01-06	2019-08-12	고려대학교 세종산학협력단	신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
MA54395A (fr)	2018-12-07	2022-03-16	Neurocrine Biosciences Inc	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
WO2021062246A1 (en)	2019-09-27	2021-04-01	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
CN115160221B (zh) *	2022-07-26	2024-10-18	恩祺生物科技(上海)有限公司	德立替尼晶型化合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW444018B (en) *	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
RU2124015C1 (ru) *	1992-12-17	1998-12-27	Пфайзер Инк.	Производные пирроло [2,3-d] пиримидинов, фармацевтическая композиция, пирроло [2,3-d] пиримидины, производные пиррола
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
CN1056611C (zh) *	1994-06-16	2000-09-20	美国辉瑞有限公司	吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
EP0729758A3 (en) *	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6020492A (en) *	1995-05-12	2000-02-01	Neurogen Corporation	Deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
ATE243697T1 (de) *	1995-12-08	2003-07-15	Pfizer	Substitutierte heterozyclische derivate als crf antagonisten

1997
- 1997-07-15 TW TW086109990A patent/TW477787B/zh not_active IP Right Cessation
- 1997-07-21 BR BR9711262A patent/BR9711262A/pt not_active Application Discontinuation
- 1997-07-21 CN CNB021020574A patent/CN1191236C/zh not_active Expired - Fee Related
- 1997-07-21 CZ CZ99677A patent/CZ67799A3/cs unknown
- 1997-07-21 ES ES97929464T patent/ES2216157T3/es not_active Expired - Lifetime
- 1997-07-21 SI SI9730642T patent/SI0925298T1/xx unknown
- 1997-07-21 CN CNB971973555A patent/CN1138774C/zh not_active Expired - Fee Related
- 1997-07-21 CA CA002263913A patent/CA2263913C/en not_active Expired - Fee Related
- 1997-07-21 DE DE69728676T patent/DE69728676T2/de not_active Expired - Fee Related
- 1997-07-21 AT AT97929464T patent/ATE264327T1/de not_active IP Right Cessation
- 1997-07-21 SK SK225-99A patent/SK22599A3/sk unknown
- 1997-07-21 EA EA199900166A patent/EA002607B1/ru not_active IP Right Cessation
- 1997-07-21 UA UA99020647A patent/UA66345C2/uk unknown
- 1997-07-21 KR KR10-1999-7001619A patent/KR100457759B1/ko not_active Expired - Fee Related
- 1997-07-21 PT PT97929464T patent/PT925298E/pt unknown
- 1997-07-21 DK DK97929464T patent/DK0925298T3/da active
- 1997-07-21 IL IL12804997A patent/IL128049A/en not_active IP Right Cessation
- 1997-07-21 JP JP10511427A patent/JP2000502722A/ja active Pending
- 1997-07-21 NZ NZ333728A patent/NZ333728A/xx unknown
- 1997-07-21 EP EP97929464A patent/EP0925298B1/en not_active Expired - Lifetime
- 1997-07-21 TR TR1999/00408T patent/TR199900408T2/xx unknown
- 1997-07-21 WO PCT/IB1997/000904 patent/WO1998008846A1/en not_active Ceased
- 1997-07-21 AU AU33557/97A patent/AU726771C/en not_active Ceased
- 1997-07-21 PL PL97331988A patent/PL331988A1/xx unknown
- 1997-07-30 PA PA19978435001A patent/PA8435001A1/es unknown
- 1997-08-13 GT GT199700093A patent/GT199700093A/es unknown
- 1997-08-21 AP APAP/P/1997/001076A patent/AP1164A/en active
- 1997-08-22 HR HR60/024,659A patent/HRP970452A2/hr not_active Application Discontinuation
- 1997-08-22 PE PE1997000751A patent/PE108698A1/es not_active Application Discontinuation
- 1997-08-25 AR ARP970103851A patent/AR009321A1/es not_active Application Discontinuation
- 1997-08-25 ID IDP972952A patent/ID18189A/id unknown
- 1997-08-26 ZA ZA977652A patent/ZA977652B/xx unknown
- 1997-08-26 TN TNTNSN97144A patent/TNSN97144A1/fr unknown
- 1997-08-26 CO CO97049282A patent/CO4930259A1/es unknown
- 1997-08-26 DZ DZ970149A patent/DZ2299A1/fr active
- 1997-08-26 YU YU35697A patent/YU35697A/sr unknown
- 1997-08-26 MY MYPI97003918A patent/MY132671A/en unknown
1999
- 1999-02-05 IS IS4970A patent/IS4970A/is unknown
- 1999-02-22 BG BG103192A patent/BG64316B1/bg unknown
- 1999-02-25 OA OA9900039A patent/OA10980A/en unknown
- 1999-02-25 NO NO19990892A patent/NO316273B1/no not_active IP Right Cessation
2001
- 2001-01-10 AR ARP010100097A patent/AR026826A1/es unknown

Also Published As

Publication number	Publication date
GT199700093A (es)	1999-02-04
CN1228091A (zh)	1999-09-08
CZ67799A3 (cs)	1999-11-17
KR100457759B1 (ko)	2004-11-18
OA10980A (en)	2001-11-02
PE108698A1 (es)	1999-01-23
EP0925298B1 (en)	2004-04-14
HK1019597A1 (en)	2000-02-18
HRP970452A2 (en)	1998-08-31
NO990892L (no)	1999-02-25
CN1367169A (zh)	2002-09-04
EP0925298A1 (en)	1999-06-30
CA2263913C (en)	2004-06-29
NZ333728A (en)	2000-11-24
DE69728676D1 (de)	2004-05-19
IS4970A (is)	1999-02-05
CA2263913A1 (en)	1998-03-05
DZ2299A1 (fr)	2002-12-25
NO316273B1 (no)	2004-01-05
KR20000035898A (ko)	2000-06-26
CN1138774C (zh)	2004-02-18
BG103192A (en)	1999-09-30
NO990892D0 (no)	1999-02-25
UA66345C2 (en)	2004-05-17
TR199900408T2 (xx)	1999-05-21
AU3355797A (en)	1998-03-19
TW477787B (en)	2002-03-01
AP9701076A0 (en)	1997-10-31
CN1191236C (zh)	2005-03-02
ID18189A (id)	1998-03-12
JP2000502722A (ja)	2000-03-07
BG64316B1 (bg)	2004-09-30
AU726771B2 (en)	2000-11-23
AR009321A1 (es)	2000-04-12
ATE264327T1 (de)	2004-04-15
SI0925298T1 (en)	2004-08-31
TNSN97144A1 (fr)	2005-03-15
IL128049A (en)	2004-12-15
EA199900166A1 (ru)	1999-08-26
PL331988A1 (en)	1999-08-16
PT925298E (pt)	2004-07-30
AU726771C (en)	2004-11-11
BR9711262A (pt)	1999-08-17
DE69728676T2 (de)	2004-09-30
AR026826A1 (es)	2003-02-26
PA8435001A1 (es)	2002-07-30
WO1998008846A1 (en)	1998-03-05
IL128049A0 (en)	1999-11-30
SK22599A3 (en)	2000-07-11
DK0925298T3 (da)	2004-08-09
AP1164A (en)	2003-06-30
ES2216157T3 (es)	2004-10-16
EA002607B1 (ru)	2002-06-27
ZA977652B (en)	1999-02-26
MY132671A (en)	2007-10-31
CO4930259A1 (es)	2000-06-27

Publication	Publication Date	Title
YU35697A (en)	1999-11-22	Substituted 6,6-hetero-bicyclic derivatives
YU40997A (sh)	2000-10-30	Novi oksadiazoli, postupci za njihovo pripremanje
AP2002002637A0 (en)	2002-09-30	Novel piperazine
YU11997A (sh)	1999-09-27	Laktamski derivati i njihove farmaceutske kompozicije
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
AR015103A1 (es)	2001-04-18	Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones que los contienen e intermediarios
YU56995A (sh)	1998-07-10	Soli derivata indola
CO4230019A1 (es)	1995-10-19	Antagonistas de neuroquinina diazabiciclica
ATE203515T1 (de)	2001-08-15	Meta-substituierte phenylsulphonamidderivate
BG103485A (en)	2000-01-31	Ketobanzamides as calpain inhibitors
CA2359772A1 (en)	2000-08-17	Cyclic substituted fused pyrrolocarbazoles and isoindolones
DK0696281T3 (da)	1999-11-01	Hidtil ukendte 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazolderivater
ATE192744T1 (de)	2000-05-15	Piperazinderivate als 5 ht1a antagonisten
BG103863A (en)	2000-07-31	Indazolamide compounds as serotoninergic forms
HRP20000585B1 (en)	2009-02-28	Substituted bisindolymaleimides for the inhibition of cell proliferation
WO2002032901A3 (en)	2002-07-25	Bridged piperazine derivatives
EA200000204A1 (ru)	2000-10-30	Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
ATE224372T1 (de)	2002-10-15	Substituierte 6-alkylphenanthridine
YU44301A (sh)	2004-07-15	5ht1 antagonisti za antidepresantnu terapiju
YU5893A (sh)	1996-07-24	Sulfonilkarbamid i postupak za njegovo dobijanje
DE69330601D1 (de)	2001-09-20	Serotoninergische ergolin derivate
NO303686B1 (no)	1998-08-17	Forbindelse til anvendelse ved fremstilling av alkylderivater av trazodon med CNS-aktivitet
YU6996A (sh)	1999-03-04	Upotreba benzotiofena za dobijanje leka
AP2002002595A0 (en)	2002-09-30	Heterocyclic amide derivatives.
DK0623620T3 (da)	1999-06-07	5-HT3-pyrrolopyrazinderivater